# Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

> **NCT00524030** · PHASE3 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 161 (actual)

## Conditions studied

- Epilepsies, Partial

## Interventions

- **DRUG:** pregabalin 600 mg/day
- **DRUG:** pregabalin 150 mg/day

## Key facts

- **NCT ID:** NCT00524030
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-06
- **Target enrollment:** 161 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524030, "Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00524030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*